

ACIP Pertussis Vaccines Working Group

Mark Sawyer

Chair, ACIP Pertussis Vaccine Working Group

Advisory Committee for Immunization Practices

February 22, 2012

Work Group Members

ACIP

Mark Sawyer, Chair
Carol Baker
Kris Ehresmann
Marietta Vazquez

CDC

Jennifer Liang, Lead
William Atkinson (ISD)
Thomas Clark
Stacey Martin
Nancy Messonnier
Pedro Moro (ISO)
Tami Skoff
Tej Tiwari
Lucia Tondella

Liaison

Richard Beigi (ACOG)
Albert Bourbon (AAPA)
Alexis Elward (HICPAC)
Stanley Gall (ACOG)
Xin-Xing Gu (NIAID)
Christine Hahn (CSTE)
Jessica Kahn (SAM)
Harry Keyserling (SHEA)
Tom Koinis (AAFP)
Sarah Long (AAP)
Kathy Neuzil (IDSA)
Jennifer Read (NVPO)
Stephanie Schauer (AIM)
Kenneth Schmader (AGS)
Ann Schwartz (FDA)
Matthew Zahn (NACCHO)

Consultants

Lance Chilton
Scott Halperin (Canada)
Bruce Meade
Peter McIntyre (Australia)

Terms of Reference

1. Review existing statements on infants and young children (1997), adolescent (2006), adults (2006), and pregnant and postpartum women and their infants (2008) and consolidate into a single statement.
2. Review new data on Tdap including
 - Effectiveness of ACIP recommendations
 - Interval between Td booster and Tdap
 - **Use of Tdap in adults ages 65 yrs and older**
 - Vaccinated health-care personnel and need for postexposure prophylaxis
 - Pregnant and breastfeeding women
 - Use of Tdap
 - Cocooning strategies
 - Revaccination*
3. Review updated epidemiology of tetanus and diphtheria

*Not part of original terms of reference

Outline of Pertussis Vaccines Session

- ❑ Update and discussion on the resurgence of pertussis in the United States
- ❑ Pertussis in older adults in the United States
- ❑ Cost effectiveness
 - Tdap substitution for Td in prevention of pertussis in adults 65 years and older (CDC)
 - Boostrix® in adults 65 years of age and older (GSK)
- ❑ Safety and immunogenicity of Boostrix in adults aged 65 years and older
- ❑ ACIP recommendation for vote
- ❑ Guidance for use of Adacel in adults aged 65 years and older

Licensed Tdap vaccines

	BOOSTRIX® (GlaxoSmithKline Biologicals)*	ADACEL™ (sanofi pasteur)†
Age Indication (years)	10 and older	11 through 64
Usage	Active booster immunization for prevention of tetanus, diphtheria, and pertussis as a <u>single</u> dose	

* Product label available at http://us.gsk.com/products/assets/us_boostrix.pdf

† Product label available at <http://www.vaccineplace.com/products/>

Current ACIP recommendations for adults

❑ Adults aged 19 through 64 years

- For adults aged 19 through 64 years who previously have not received a dose of Tdap, a single dose of Tdap should replace a single decennial Td booster dose.

❑ Adults aged 65 years and older

- Adults aged 65 years and older (e.g., grandparents, child-care providers, and health care practitioners) who have or who anticipate having close contact with an infant less than 12 months of age and who previously have not received Tdap should receive a single dose of Tdap.
- For other adults aged 65 years and older, a single dose of Tdap vaccine may be given instead of Td vaccine, in persons who have not previously received Tdap.
- Either Tdap vaccine product may be used.

What's next for WG

- ❑ Updating ACIP Pertussis Vaccines statement (2012)
- ❑ Tdap revaccination (not included in revised statement)